Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2011

01.11.2011 | Preclinical study

CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways

verfasst von: Ji-Hong Lim, Tae-You Kim, Woo-Ho Kim, Jong-Wan Park

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Calcium-modulating cyclophilin ligand (CAML) interacts with the intracellular regions of various types of membrane-bound receptors, and is required for signaling pathways that involve these receptors. The authors tested the possibility that CAML interacts with prolactin receptor (PRLR) and participates in the prolactin (PRL)-dependent proliferation of breast cancer cells. Breast cancer cell lines were found to express CAML at higher levels than cell lines originating from leukemia and other cancers. Furthermore, immunohistochemical analyses of breast tissue arrays showed that the CAML levels were higher in cancer tissues than in normal tissues. In breast cancer cells and transfected HEK293 cells, CAML associated with PRLR, and this interaction was augmented during PRL stimulation. CAML-silencing experiments revealed that CAML is required for the functions of PRLR, such as, the activations of Stat5 and Mek1/2, PRL internalization with cyclophilin B, PRLR recycling, and increased Ca2+ mobilization. In addition, CAML was found to play a crucial role in the PRL/PRLR-dependent growth of breast cancer cells. These results suggest a new role for CAML in breast cancer development.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639–669PubMed Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639–669PubMed
2.
Zurück zum Zitat Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268PubMedCrossRef Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268PubMedCrossRef
3.
Zurück zum Zitat Naylor MJ, Lockefeer JA, Horseman ND, Ormandy CJ (2003) Prolactin regulates mammary epithelial cell proliferation via autocrine/paracrine mechanism. Endocrine 20:111–114PubMedCrossRef Naylor MJ, Lockefeer JA, Horseman ND, Ormandy CJ (2003) Prolactin regulates mammary epithelial cell proliferation via autocrine/paracrine mechanism. Endocrine 20:111–114PubMedCrossRef
4.
Zurück zum Zitat Harris J, Stanford PM, Oakes SR, Ormandy CJ (2004) Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med 36:414–425PubMedCrossRef Harris J, Stanford PM, Oakes SR, Ormandy CJ (2004) Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med 36:414–425PubMedCrossRef
5.
Zurück zum Zitat Clevenger CV, Furth PA, Hankinson SE, Schuler LA (2003) The role of prolactin in mammary carcinoma. Endocr Rev 24:1–27PubMedCrossRef Clevenger CV, Furth PA, Hankinson SE, Schuler LA (2003) The role of prolactin in mammary carcinoma. Endocr Rev 24:1–27PubMedCrossRef
6.
Zurück zum Zitat Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, Rosen JM, Robinson GW, Hennighausen L (2001) Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 155:531–542PubMedCrossRef Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, Rosen JM, Robinson GW, Hennighausen L (2001) Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 155:531–542PubMedCrossRef
7.
Zurück zum Zitat Clevenger CV, Gadd SL, Zheng J (2009) New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab 20:223–229PubMedCrossRef Clevenger CV, Gadd SL, Zheng J (2009) New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab 20:223–229PubMedCrossRef
8.
Zurück zum Zitat Das R, Vonderhaar BK (1996) Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat 40:141–149PubMedCrossRef Das R, Vonderhaar BK (1996) Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat 40:141–149PubMedCrossRef
9.
Zurück zum Zitat Tessier C, Prigent-Tessier A, Ferguson-Gottschall S, Gu Y, Gibori G (2001) PRL antiapoptotic effect in the rat decidua involves the PI3 K/protein kinase B-mediated inhibition of caspase-3 activity. Endocrinology 142:4086–4094PubMedCrossRef Tessier C, Prigent-Tessier A, Ferguson-Gottschall S, Gu Y, Gibori G (2001) PRL antiapoptotic effect in the rat decidua involves the PI3 K/protein kinase B-mediated inhibition of caspase-3 activity. Endocrinology 142:4086–4094PubMedCrossRef
10.
Zurück zum Zitat Rycyzyn MA, Clevenger CV (2002) The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 99:6790–6795PubMedCrossRef Rycyzyn MA, Clevenger CV (2002) The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 99:6790–6795PubMedCrossRef
11.
Zurück zum Zitat Bram RJ, Crabtree GR (1994) Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. Nature 371:355–358PubMedCrossRef Bram RJ, Crabtree GR (1994) Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. Nature 371:355–358PubMedCrossRef
12.
Zurück zum Zitat von Bülow GU, Bram RJ (1997) NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278:138–141CrossRef von Bülow GU, Bram RJ (1997) NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278:138–141CrossRef
13.
Zurück zum Zitat Holloway MP, Bram RJ (1996) A hydrophobic domain of Ca2 + -modulating cyclophilin ligand modulates calcium influx signaling in T lymphocytes. J Biol Chem 271:8549–8852PubMedCrossRef Holloway MP, Bram RJ (1996) A hydrophobic domain of Ca2 + -modulating cyclophilin ligand modulates calcium influx signaling in T lymphocytes. J Biol Chem 271:8549–8852PubMedCrossRef
14.
Zurück zum Zitat Holloway MP, Bram RJ (1998) Co-localization of calcium-modulating cyclophilin ligand with intracellular calcium pools. J Biol Chem 273:16346–16350PubMedCrossRef Holloway MP, Bram RJ (1998) Co-localization of calcium-modulating cyclophilin ligand with intracellular calcium pools. J Biol Chem 273:16346–16350PubMedCrossRef
15.
Zurück zum Zitat Tran DD, Russell HR, Sutor SL, van Deursen J, Bram RJ (2003) CAML is required for efficient EGF receptor recycling. Dev Cell 5:245–256PubMedCrossRef Tran DD, Russell HR, Sutor SL, van Deursen J, Bram RJ (2003) CAML is required for efficient EGF receptor recycling. Dev Cell 5:245–256PubMedCrossRef
16.
Zurück zum Zitat Guang W, Kim KC, Lillehoj EP (2009) MUC1 mucin interacts with calcium-modulating cyclophilin ligand. Int J Biochem Cell Biol 41:1354–1360PubMedCrossRef Guang W, Kim KC, Lillehoj EP (2009) MUC1 mucin interacts with calcium-modulating cyclophilin ligand. Int J Biochem Cell Biol 41:1354–1360PubMedCrossRef
17.
Zurück zum Zitat Yuan X, Yao J, Norris D, Tran DD, Bram RJ, Chen G, Luscher B (2008) Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABA(A) receptors. Mol Cell Neurosci 38:277–289PubMedCrossRef Yuan X, Yao J, Norris D, Tran DD, Bram RJ, Chen G, Luscher B (2008) Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABA(A) receptors. Mol Cell Neurosci 38:277–289PubMedCrossRef
18.
Zurück zum Zitat Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG, Kanakura Y (1999) Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 18:1367–1377PubMedCrossRef Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG, Kanakura Y (1999) Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 18:1367–1377PubMedCrossRef
19.
20.
Zurück zum Zitat Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Törnell J (1997) Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100:2744–2751PubMedCrossRef Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Törnell J (1997) Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100:2744–2751PubMedCrossRef
21.
Zurück zum Zitat Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA (2003) Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22:4664–4674PubMedCrossRef Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA (2003) Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22:4664–4674PubMedCrossRef
22.
Zurück zum Zitat Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE (1995) Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 146:695–705PubMed Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE (1995) Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 146:695–705PubMed
23.
Zurück zum Zitat Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV (1997) Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138:5555–5560PubMedCrossRef Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV (1997) Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138:5555–5560PubMedCrossRef
24.
Zurück zum Zitat Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE (1999) Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91:629–634PubMedCrossRef Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE (1999) Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91:629–634PubMedCrossRef
25.
Zurück zum Zitat Gill S, Peston D, Vonderhaar BK, Shousha S (2001) Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 54:956–960PubMedCrossRef Gill S, Peston D, Vonderhaar BK, Shousha S (2001) Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 54:956–960PubMedCrossRef
26.
Zurück zum Zitat Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, Chikhlikar PR, Trivedi TI (2000) Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 26:540–547PubMedCrossRef Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, Chikhlikar PR, Trivedi TI (2000) Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 26:540–547PubMedCrossRef
27.
Zurück zum Zitat Alvarez RH, Valero V, Hortobagyi GN (2010) Emerging targeted therapies for breast cancer. J Clin Oncol 28:3366–3379PubMedCrossRef Alvarez RH, Valero V, Hortobagyi GN (2010) Emerging targeted therapies for breast cancer. J Clin Oncol 28:3366–3379PubMedCrossRef
28.
Zurück zum Zitat Di Cosimo S, Baselga J (2008) Targeted therapies in breast cancer: where are we now? Eur J Cancer 44:2781–2790PubMedCrossRef Di Cosimo S, Baselga J (2008) Targeted therapies in breast cancer: where are we now? Eur J Cancer 44:2781–2790PubMedCrossRef
Metadaten
Titel
CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways
verfasst von
Ji-Hong Lim
Tae-You Kim
Woo-Ho Kim
Jong-Wan Park
Publikationsdatum
01.11.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1274-4

Weitere Artikel der Ausgabe 1/2011

Breast Cancer Research and Treatment 1/2011 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.